http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-079555-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40765ca9a78b54a8a76f781d159ad145 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 |
| filingDate | 2010-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-079555-A1 |
| titleOfInvention | METHODS OF TREATMENT OF INFECTION OF HEPATITIS B (HBV) VIRUS AND HEPATITIS C (HCV) VIRUS |
| abstract | Claim 1: A method for the treatment of a viral hepatitis B infection, comprising administering to a human subject infected with the hepatitis B virus, a therapeutically effective amount of: (1) or a pharmaceutically active salt thereof. acceptable. Claim 16: The method of claim 15, wherein the additional therapeutic agent is selected from the group consisting of lamivudine, adefovir, tenofovir, telbivudine, entecavir, interferon alfa-2b, pegylated interferon alfa-2a, interferon alfa 2a, interferon alfa Nl , prednisone, predinisolone, Thymalfasin «, retinoic acid receptor agonists, 4-methylumbelliferone, Alamifovir«, Metacavir «, Albuferon«, cytokines and TolI type receptor agonists. Claim 26: A method for the treatment of a viral hepatitis C infection, comprising administering to a human subject infected with the hepatitis C virus, a therapeutically effective amount of (1) or a pharmaceutically acceptable salt thereof. Claim 40: The method of claim 26, further comprising administering an additional therapeutic agent to humans. Claim 41: The method of claim 40, wherein the additional therapeutic agent is selected from the group consisting of interferons, ribavirin or its analogs, NS3 HCV protease inhibitors, alpha-glucosidase 1 inhibitors, HCV nucleoside or nucleotide inhibitors NS5B polymerase, non-nucleoside HCV inhibitors NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonists, cyclophilin inhibitors and IRES HCV inhibitors. |
| priorityDate | 2009-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.